Leap Therapeutics(US:LPTX) Prnewswireยท2025-04-15 11:00Core Viewpoint - Leap Therapeutics is hosting a virtual KOL event to discuss the potential of sirexatamab (DKN-01) in treating advanced microsatellite stable colorectal cancer, highlighting its clinical data and unmet medical needs [1][2][3] Company Overview - Leap Therapeutics, Inc. is a biotechnology company focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being sirexatamab, a humanized monoclonal antibody targeting the DKK1 protein [5] - The company is also developing FL-501, another humanized monoclonal antibody targeting GDF-15, which is currently in preclinical development [5] Event Details - The virtual KOL event will feature Dr. Zev A. Wainberg from UCLA, who will discuss the unmet needs in treating advanced MSS colorectal cancer and the potential improvements offered by sirexatamab [1][2] - The event will review positive data from Part B of the Phase 2 DeFianCe study, focusing on second-line patients with advanced MSS CRC [3] - A live Q&A session will follow the discussion, and a replay will be available on the company's investor page [3] Research and Development - Dr. Wainberg's research includes clinical trials for various gastrointestinal cancers, and he is currently focused on targeting cancer stem cells and molecular classification of gastrointestinal cancers [4] - Sirexatamab is being studied specifically for its efficacy in patients with colorectal cancer, addressing a significant unmet need in the treatment landscape [2][5]